A groundbreaking clinical trial has unveiled a structured, sustainable methodology that significantly reduces maternal infections and deaths, underpinning a new strategy in infection prevention and treatment. This program, known as the Active Prevention and Treatment of Maternal Sepsis (APT-Sepsis), was collaboratively developed by researchers at the University of Liverpool, the World Health Organization (WHO), and…
LPOXY Therapeutics, a pioneering biopharmaceutical corporation in the clinical development phase, is making notable strides in developing a preventive method for Clostridioides difficile infections that does not involve antibiotics. The company recently signed an agreement with 5Horizons Ventures, a recognized venture capital firm specializing in life sciences, with a proven track record of supporting revolutionary…
The Digestive Disease Week conference in San Diego unveiled compelling new analysis from a recent Phase 3 clinical trial. The findings suggest that a live biotherapeutic, primarily used to prevent the recurrence of Clostridioides difficile infection, may also enhance mental health parameters, creating a significant correlation with alterations in the gut's microbiome and metabolome. Patients…